Recent advances in cancer immunotherapy

Qiang Sun, Gerry Melino, Ivano Amelio, Jingting Jiang, Ying Wang, Yufang Shi

Research output: Contribution to journalReview articlepeer-review


Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.

Original languageEnglish (US)
Article number27
JournalDiscover Oncology
Issue number1
StatePublished - Dec 2021
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrine and Autonomic Systems


  • Cancer immunotherapy
  • Cancer survival
  • Immune check point blockade
  • KRas
  • T cell receptor
  • p53


Dive into the research topics of 'Recent advances in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this